Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.
Metastatic Colorectal Cancer
DRUG: Capecitabine+Irinotecan+Bevacizumab
Progression free survival (PFS), 2009-2012
overall survival (SG), 2009-2012|Overall Response rate, 2009-2012|Toxicity, 2009-2012|Duration of response, 2009-2012|Quality of life, 2009-2012|Rate of hepatic metastases resection, 2009-2012
The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks
* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks
* Bevacizumab: 5 mg/kg day 1, every 2 Weeks